Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours

被引:157
作者
Langer, C
Gunawan, B
Schüler, P
Huber, W
Füzesi, L
Becker, H
机构
[1] Univ Gottingen, Dept Gen Surg, D-37075 Gottingen, Germany
[2] Univ Gottingen, Dept Pathol, D-37075 Gottingen, Germany
[3] German Canc Res Ctr, Div Mol Genome Anal, D-6900 Heidelberg, Germany
关键词
D O I
10.1002/bjs.4046
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The purpose of this study was to review surgical experience with gastrointestinal stromal tumours (GISTs) at a single tertiary university hospital, and to identify morphological and genetic prognostic markers of tumour progression. Methods: Forty-eight GISTs from 39 patients were reviewed retrospectively. The prognostic significance of DNA copy number changes, measured by comparative genomic hybridization (CGH), and morphological markers in low-risk and high-risk tumours were investigated. Results: Significantly more patients died from disease after incomplete tumour resection than after complete primary resection (P = 0020). Tumour size of 5 cm or greater, mitotic count of 2 or more, and proliferative activity greater than 10 per cent were significantly associated with a shorter recurrence-free survival (P = 0020, P = 0001 and P = 0.002 respectively). Patients with low-risk tumours had a significantly better outcome than those with high-risk GISTs, both in terms of overall and recurrence-free survival (P less than or equal to 0.001). CGH performed on 16 tumours revealed fewer DNA sequence copy number changes in low-risk than in high-risk GISTs. Non-progressive GISTs contained significantly fewer genetic alterations than recurrent or metastatic tumours (P < 0.001). Only tumours with more than five changes showed disease progression. Conclusion: Complete surgical resection is the most important means of cure for GISTs. DNA copy number changes are related to the behaviour of these tumours and may serve as additional prognostic markers.
引用
收藏
页码:332 / 339
页数:8
相关论文
共 36 条
[1]  
BANDOH T, 1993, SURGERY, V113, P498
[2]  
Bergmann F, 1998, PROCEEDINGS OF THE GERMAN SOCIETY FOR PATHOLOGY 82ND MEETING - 1998, P275
[3]  
Biesterfeld S, 1998, J PATHOL, V185, P25, DOI 10.1002/(SICI)1096-9896(199805)185:1<25::AID-PATH40>3.0.CO
[4]  
2-R
[5]   Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors) [J].
Breiner, JA ;
Meis-Kindblom, J ;
Kindblom, LG ;
McComb, E ;
Lin, J ;
Nelson, M ;
Bridge, JA .
CANCER GENETICS AND CYTOGENETICS, 2000, 120 (02) :111-116
[6]   Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: A clinic comparison [J].
Clary, BM ;
DeMatteo, RP ;
Lewis, JJ ;
Leung, D ;
Brennan, MF .
ANNALS OF SURGICAL ONCOLOGY, 2001, 8 (04) :290-299
[7]   Two hundred gastrointestinal stromal tumors - Recurrence patterns and prognostic factors for survival [J].
DeMatteo, RP ;
Lewis, JJ ;
Leung, D ;
Mudan, SS ;
Woodruff, JM ;
Brennan, MF .
ANNALS OF SURGERY, 2000, 231 (01) :51-58
[8]  
El-Rifai W, 2000, CANCER RES, V60, P3899
[9]   Prognosis of gastrointestinal smooth-muscle (Stromal) tumors - Dependence on anatomic site [J].
Emory, TS ;
Sobin, LH ;
Lukes, L ;
Lee, DH ;
O'Leary, TJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1999, 23 (01) :82-87
[10]  
EVANS HL, 1985, CANCER, V56, P2242, DOI 10.1002/1097-0142(19851101)56:9<2242::AID-CNCR2820560918>3.0.CO